Uniphar plc

Full Year Trading Update and Notice of Results

Dublin, London | 27 January 2026: Uniphar plc (the "Group" or "Uniphar"), an international diversified healthcare services business, today announces the following unaudited trading update for the year ended 31 December 2025.

The business achieved ca. 21% adjusted EPS growth in 2025, ahead of the Group's expectations. This was driven by a strong trading performance with ca. 9% organic gross profit growth, lower finance costs and accretion from the €35m share buy-back programme.

The Group continues to maintain a strong liquidity position, with lower-than-expected Net Bank Debt/EBITDA of 1.5x at year end, due to favourable working capital movements.

Outlook

Uniphar is well positioned to deliver organic gross profit growth across all divisions and, consistent with the Group's medium-term targets, is expecting organic gross profit growth in 2026 as follows:

•           Uniphar Pharma: Double digit

•           Uniphar Medtech: High single digit

•           Uniphar Supply Chain & Retail: Low single digit

M&A continues to play an important role in Uniphar's growth strategy, and the Group maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance the Group's growth potential.

Ger Rabbette, Uniphar Group Chief Executive Officer said:

"2025 was another great year for Uniphar, with all our divisions contributing to our fastest rate of organic gross profit growth since IPO. This underscores the positive impact that our strategy is having on our ability to scale organically. We have now delivered an excellent six-year EPS CAGR of 16%.  We remain confident of reaching our €200m EBITDA target by 2028, with at least 80% of our growth being organic."

Notice of Results

The Group expects to publish its final results for the year ended 31 December 2025 at 07:00 am (GMT) on 24 February 2026.

A conference call for analysts and investors will be held at 9:00 am (GMT) on 24 February 2026 to discuss the Group's final results. Analysts and investors who wish to participate should visit www.uniphar.ie to register. 

The Company's final results press release and presentation will also be available on the website at 07:00 am (GMT) on 24 February 2026 at www.uniphar.ie.

--- ENDS ---

Contact details

About Uniphar plc 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.